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Abstract

Background

Key words: Trial-ready cohort, Alzheimer’s disease, machine learning.

creening cognitively normal older individuals
for the presence of elevated cerebral amyloidbeta protein (“Aβ+”) and inclusion in secondary
prevention trials for Alzheimer’s disease (AD) is invasive,
expensive and slow. The current gold standards to
measure Amyloid-β in the brain require either positron
emission tomography (PET) or cerebrospinal fluid (CSF)
assay. For example, the Anti-Amyloid Treatment in
Asymptomatic Alzheimer’s disease (A4) trial conducted
amyloid PET on 4,486 individuals in order to identify
1,323 Aβ+ individuals for an amyloid PET screen fail
rate of 71% (1). The Number Needed to Screen (NNS) to
identify each Aβ+ individual was 3.39 individuals.
Trial-Ready Cohort in Preclinical/Prodromal
Alzheimer’s Disease (TRC-PAD) is a research program
that was initiated to find solutions to these challenges in
trial recruitment and site management, as described in
Aisen, et al. Submitted (2). There are three elements that
make up the TRC-PAD platform; Alzheimer’s Prevention
Trial (APT) webstudy (aptwebstudy.org), Site Referral
System (SRS) and the Trial Ready Cohort (TRC). The APT
webstudy invites participants to enroll into the study.
At the time of enrollment, participants are asked for
demographic, medical and lifestyle information. They
are asked to complete longitudinal web-based cognitive
testing and symptom questionnaires. With these data,
we aim to estimate the likelihood that an individual is
Aβ+ before they are invited to participate in a secondary
prevention trial. The SRS helps facilitate the participants
deemed to be most likely Aβ+ from APT to go for
in-clinic assessments where they proceed with the TRC
screening. During the TRC screening phase participants
are administered additional testing, including Preclinical
Alzheimer’s Cognitive Composite (PACC) (3) and
genotyping, before assessing their eligibility for an
amyloid test.
In this paper, we describe how the prediction models
and algorithms used in TRC-PAD were derived from A4

BACKGROUND: Screening to identify individuals with
elevated brain amyloid (Aβ+) for clinical trials in Preclinical
Alzheimer’s Disease (PAD), such as the Anti-Amyloid
Treatment in Asymptomatic Alzheimer’s disease (A4) trial,
is slow and costly. The Trial-Ready Cohort in Preclinical/
Prodromal Alzheimer’s Disease (TRC-PAD) aims to accelerate
and reduce costs of AD trial recruitment by maintaining a
web-based registry of potential trial participants, and using
predictive algorithms to assess their likelihood of suitability for
PAD trials.
OBJECTIVES: Here we describe how algorithms used to predict
amyloid burden within TRC-PAD project were derived using
screening data from the A4 trial.
DESIGN: We apply machine learning techniques to predict
amyloid positivity. Demographic variables, APOE genotype,
and measures of cognition and function are considered as
predictors. Model data were derived from the A4 trial.
SETTING: TRC-PAD data are collected from web-based and
in-person assessments and are used to predict the risk of
elevated amyloid and assess eligibility for AD trials.
PARTICIPANTS: Pre-randomization, cross-sectional data from
the ongoing A4 trial are used to develop statistical models.
MEASUREMENTS: Models use a range of cognitive tests and
subjective memory assessments, along with demographic
variables. Amyloid positivity in A4 was confirmed using
positron emission tomography (PET).
RESULTS: The A4 trial screened N=4,486 participants, of which
N=1323 (29%) were classified as Aβ+ (SUVR ≥ 1.15). The Area
under the Receiver Operating Characteristic curves for these
models ranged from 0.60 (95% CI 0.56 to 0.64) for a web-based
battery without APOE to 0.74 (95% CI 0.70 to 0.78) for an
in-person battery. The number needed to screen to identify an
Aβ+ individual is reduced from 3.39 in A4 to 2.62 in the remote
setting without APOE, and 1.61 in the remote setting with
APOE.
CONCLUSIONS: Predictive algorithms in a web-based registry
can improve the efficiency of screening in future secondary
prevention trials. APOE status contributes most to predictive
accuracy with cross-sectional data. Blood-based assays of
amyloid will likely improve the prediction of amyloid PET
positivity.
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Table 1. Predictors Considered
Abbreviation

Variable

Description

Remote

In Clinic

Age

Age

Number of years

√

√

Edu

Education

Number of years

√

√

Sex

Sex

Male or Female

√

√

OCL

Cogstate One Card Learning

Accuracy

√

OBR

Cogstate One Back Reaction

Reaction time

√

DER

Cogstate Detection Reaction

Reaction time

√

IDR

Cogstate Identification Reaction

Reaction time

√

FH

Family History

Family history a parent or sibling with AD

√

FH P

Family History - Parent

Family history a parent with AD

FH S

Family History - Sibling

Family history a sibling with AD

CFI Pt

Cognitive Function Instrument - Participant

√
√
√

√

CFI SP

Cognitive Function Instrument - Study Partner

√

ADL Pt

Activities of Daily Living - Participant

√

ADL SP

Activities of Daily Living - Study Partner

√

PACC

Preclinical Alzheimer Cognitive Composite

APOE4

APOEε4

√
(X/ √)

(X/ √)

We considered predictive algorithms which could be applied to data captured either remotely via a web-based registry, or in the clinic (though all data in A4 was collected
in clinic), as indicated in the table. In all we considered 6 models: (1) remote battery with APOE, (2) remote battery without APOE, (3) in clinic battery with APOE, (4) in
clinic battery without APOE, (5) in clinic battery with individual PACC component scores and APOE, and (6) in clinic battery with individual PACC component scores
without APOE.

screening data. We anticipate blood-based biomarkers
will greatly improve predictions of amyloid positivity,
and this is a focus of future work and an aim of TRCPAD. Predictors in the current analysis are limited to
demographics, cognitive and functional assessments, and
APOE genotype.

participants were more likely to have a family history of
dementia and at least one APOEε4 allele. In addition,
Aβ+ participants performed worse on the screening
Preclinical Alzheimer Cognitive Composite (PACC)
results and had higher scores on the Cognitive Function
Index.

Methods

Variables

Population and Study Design

Table 1 describes the collections of predictors that we
considered to train different predictive algorithms. All
screening data for the A4 Study were collected during
supervised clinic visits. However some components of
the A4 screening battery are being captured remotely
in the APT webstudy, including demographic, Cogstate
brief battery (9), family history (sibling or parent with
Alzheimer’s), and Cognitive Function Instrument
(10) (CFI) variables indicated in Table 1. We consider
predictive algorithms using these “remote” variables
only, as well as a more thorough battery that would
require a supervised clinic visit with an administration
of the PACC3. In all, we considered 6 models: (1) remote
battery without APOE, (2) remote battery with APOE,
(3) in clinic battery without APOE, (4) in clinic battery
with APOE, (5) in clinic battery with individual PACC
component scores without APOE, and (6) in clinic
battery with individual PACC component scores with
APOE. The PACC component scores include the MiniMental State Exam (MMSE) (11), Wechsler Memory ScaleRevised Logical Memory, Digit Symbol Substitution

The study design and screening data for A4 have
been previously described (7, 8) and Institutional Review
Boards have approved both A4 and TRC-PAD studies.
The A4 screening dataset contains N=4,486 participants,
of which 1323 (29%) were classified as Aβ+. Amyloid
PET imaging was conducted with florbetapir F18 and
summarized by mean cortical standardized uptake
value ratio (SUVR) relative to the whole cerebellum.
Participants were considered eligible to continue
screening for A4 based on an algorithm combining both
quantitative SUVR (≥1.15) and qualitative visual read
performed at a central laboratory. A SUVR between
1.10 and 1.15 was considered to be elevated amyloid
only if the visual read was considered positive by a
two-reader consensus determination. Participants who
were considered Aβ+ were slightly older; with mean/
standard deviation (SD) age of 72.10/4.89 in the Aβ+
group and 70.95/4.53 in the Aβ- group. However, there
were no observed differences in sex and education. Aβ+

214

JPAD - Volume 7, Number 4, 2020

Figure 1. Contribution of 5 best predictors in each model

Using the model training data we see the contribution to prediction accuracy expressed in terms of the mean absolute SHAP value (mean|SHAP|). Abbreviations: SHAP,
SHapley Additive explanation; OCL, One Card Learning; OBR, One Back Reaction; DER, Detection Reaction; IDR, Identification Reaction; FH, Family History; FH P, FH
Parent; FH S, FH Sibling; CFI, Cognitive Function Index; CFI Pt, CFI Participant; CFI SP, CFI Study Partner; ADL, Activities of Daily Living; ADL Pt, ADL Participant; ADL
SP, ADL Study Partner; PACC, Preclinical Alzheimer Cognitive Composite

(DSST), and Free and Cued Selective Reminding Test
(FCSRT) (12).

Statistical Analysis
Extreme Gradient Boosting (XGBoost) (4) is a decision
tree-based machine learning technique (6). A single
decisions tree, or regression tree, is easy to interpret
but provides relatively poor prediction. Aggregating a
large number of trees can improve prediction accuracy.
Boosting is a technique in which models are trained

in sequence, with each new model making cumulative
improvements. At each iteration the data are re-weighted
such that misclassified data points receive larger weights.
XGBoost is a scalable tree boosting algorithm, that is
optimized and designed to be highly efficient, flexible,
and portable.
XGBoost supports monotone constraints and
customized objective functions. We applied monotone
constraints to predictors such as age, number of
APOEε4 alleles (0, 1 or 2), and assessment scores that
we expect to have a generally monotonic relationship
with amyloid PET SUVR (Supplemental Figure 1). The

215

PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS

Table 2. Operating characteristics of screening algorithms using the test data with Aβ+ set to SUVR ≥ 1.15
Model

SUVR Threshold

Accuracy

Sensitivity

Specificity

NPV

PPV

NNS

Remote

1.05

54.88%

60.70%

52.77%

78.72%

31.81%

3.14

Remote with APOE

1.04

61.86%

74.24%

57.37%

85.99%

38.72%

2.58

In Clinic

1.04

57.21%

62.45%

55.31%

80.23%

33.65%

2.97

In Clinic with APOE

1.04

62.33%

73.80%

58.16%

85.95%

39.03%

2.56

In Clinic PACC

1.04

56.63%

58.95%

55.78%

78.92%

32.61%

3.07

In Clinic PACC with APOE

1.04

62.67%

73.80%

58.64%

86.05%

39.30%

2.54

Remote

1.15

71.98%

10.04%

94.45%

74.31%

39.66%

2.52

Remote with APOE

1.15

77.09%

35.81%

92.08%

79.81%

62.12%

1.61

In Clinic

1.15

72.44%

5.68%

96.67%

73.85%

38.24%

2.62

In Clinic with APOE

1.15

76.51%

36.24%

91.13%

79.75%

59.71%

1.67

In Clinic PACC

1.15

73.60%

6.55%

97.94%

74.28%

53.57%

1.87

In Clinic PACC with APOE

1.15

75.00%

28.38%

91.92%

77.96%

56.03%

1.78

The top half of the table provides operating characteristics when a threshold is applied to predicted amyloid PET SUVR that results in a 50% prediction prevalence (half of
the screening pool is predicted positive and tested with a PET scan). The first column indicates the threshold required to attain 50% prediction prevalence. The bottom half
of the table applies a threshold of 1.15, which reduces Number Need to Screen (NNS), but also greatly reduces sensitivity. The NNS is the inverse of the Positive Predictive
Value (PPV). The PPV indicates the percentage of participants that are truly positive when the model indicates them as positive. Likewise, the Negative Predictive Value
(NPV), this gives the probability that a participant is truly amyloid negative when the model indicates them as negative.

Table 3. Demographic characteristics of amyloid positive selections from the test data with Aβ+ set to SUVR ≥ 1.15
APOE4
Model

SUVR Threshold

0

Family History

1

2

No

Sex

Yes

Female

Male

Remote

1.05

298 (68.19%)

123 (28.15%)

16 (3.66%)

140 (32.04%)

297 (67.96%)

248 (56.75%)

189 (43.25%)

Remote with APOE

1.04

169 (38.50%)

240 (54.67%)

30(6.83%)

117 (26.65%)

322 (73.35%)

248 (56.49%)

191 (43.51%)

In Clinic

1.04

283 (66.59%)

128 (30.12%)

14 (3.29%)

112 (26.35%)

313 (73.65%)

248 (58.35%)

177 (41.65%)

In Clinic with APOE

1.04

175 (40.42%)

228 (52.66%)

30 (6.93%)

120 (27.71%)

313 (72.29%)

240 (55.43%)

193 (44.57%)

In Clinic PACC

1.04

281 (67.87%)

119 (28.74%)

14 (3.38%)

106 (25.60%)

308 (74.40%)

246 (59.42%)

168 (40.58%)

In Clinic PACC with APOE

1.04

177 (41.16%)

223 (51.86%)

30 (6.98%)

100 (23.26%)

330 (76.74%)

256 (59.53%)

174 (40.47%)

Remote

1.15

39 (67.24%)

17 (29.31%)

2 (3.45%)

6 (10.34%)

52 (89.66%)

27 (46.55%)

31 (53.45%)

Remote with APOE

1.15

6 (4.55%)

96 (72.73%)

30 (22.73%)

30 (22.73%)

102 (77.27%)

67 (50.76%)

65 (49.24%)

In Clinic

1.15

26 (76.47%)

8 (23.53%)

0 (0.00%)

7 (20.59%)

27 (79.41%)

15 (44.12%)

19 (55.88%)

In Clinic with APOE

1.15

22 (15.83%)

88 (63.31%)

29 (20.86%)

34 (24.46%)

105 (75.54%)

67 (48.2%)

72 (51.80%)

In Clinic PACC

1.15

16 (57.14%)

12 (42.86%)

0 (0.00%)

4 (14.29%)

24 (85.71%)

16 (57.14%)

12 (42.86%)

In Clinic PACC with APOE

1.15

18 (15.52%)

68 (58.62%)

30 (25.86%)

27 (23.28%)

89 (76.72%)

55 (47.41%)

61 (52.59%)

The top half of the table provides demographic characteristics when a threshold is applied to predicted amyloid PET SUVR that results in a 50% prediction prevalence
(half of the screening pool is predicted positive and tested with a PET scan). The first column indicates the threshold required to attain 50% prediction prevalence. The
bottom half of the table applies a threshold of 1.15. We can see in all the scenarios where APOE is included in the model, at least 29 of the 30 participants with APOE4 2
allele (in the test data) have been selected.

default XGBoost objective function is mean squared
loss, meaning decision trees are selected to minimize
the residual sum of squares. Because XGBoost does
not provide confidence intervals with mean squared
loss, we applied the Quantile Regression loss function
to estimate the 50%, 2.5%, and 97.5% quantiles of the
predictions. XGBoost model has a number of hyperparameters that are used to assist in the issue known as
the bias-variance trade-off (13). Hyper-parameters are
fixed before the model is fitted and are not learned from
data. We used 10-fold Cross-Validation (CV) to assess
the out-of-sample bias and variance for given hyperparameter values, and Bayesian Optimization (14) to

optimize the hyper-parameter selection. We use SHapley
Additive exPlanation (SHAP) (15) values to summarize
the importance of each predictor to the overall predictive
accuracy of each model. More details about the model
fitting procedures are provided in the supplemental
material (Supplemental Table 1). Our main interest lies in
the predictive accuracy of the models. In order to assess
this, we split the data randomly into 80% training and
20% test. After fitting the models with the training data,
we assess their predictive accuracy with the independent
test data. Analyses were conducted with R version 3.6.2
(r-project.org) with packages xgboost (4) version 0.90.0.2
and mlrMBO (16) version 1.1.2.

216

JPAD - Volume 7, Number 4, 2020

APOE and 2.5 participants without APOE. However, this
results in much lower sensitivity, and as we can see from
Figure 3, a threshold of 1.15 would be practical only with
participant registries of 10,000-13,000 to identify 1,000
Aβ+ participants.

Figure 2. ROC curves and AUCs

Figure 3. Number needed to screen and required
registry size

ROCs and AUCs for each model are determined using the independent test set and
Aβ+ set to SUVR ≥ 1.15. The colors represent the setting type; Remote (red), In-Clinic (blue) and PACC components (blue). Abbreviations: ROC, Receiver Operating
Characteristic; AUC, Area Under the Curve; PACC, Preclinical Alzheimer Cognitive
Composite

Results
Figure 1 shows the relative contributions, in terms
of SHAP values, for each predictor to the predictive
accuracy of each model. As expected, when available,
APOE genotype is the most important predictor for these
cross-sectional models. We see that age, CFI, education,
and family history also enter the top 5 most valuable
predictors in some models. Figure 2, the Receiver
Operating Characteristic (ROC) curves and Area under
the Curve (AUC) for the 6 models, also demonstrates
the relative value of APOE. The dashed lines are models
fitted without the APOEε4 variable and the solid lines
are for models that include APOEε4. The ROC curves
were generated using a cut point SUVR value of 1.15
for a binary separation between amyloid positive and
negative. In general, we see AUCs in the range 0.60
(without APOE) to 0.73 (with APOE).
Figure 3 expresses prediction accuracy in terms of
screening for a clinical trial. The top panel shows 1/
Positive Predictive Value (PPV), which is equivalent
to the number needed to screen (with amyloid PET) to
identify one eligible participant. In this figure, movement
along the horizontal axis represents varying the threshold
applied to SUVRs predicted from each model. The
bottom panel provides the required number of potential
participants (e.g. webstudy participants) in order to
identify 1,000 Aβ+ participants.
Table 2 reports operating characteristics from several
screening algorithm scenarios. The top half provides
operating characteristics when a threshold is selected to
provide 50% prediction prevalence (i.e. select half the
participant pool to receive amyloid PET scans). With 50%
prediction prevalence, the NNS is about 2.5 participants
with APOE and 3.0 participants without APOE. When
the threshold for predicted amyloid PET is increased to
1.15, the NNS is reduced to about 1.7 participants with

The top panel shows the number needed to screen (which is equivalent to 1/PPV)
with amyloid PET to identify one Aβ+ individual by applying the given SUVR
threshold to the values predicted from each model. The middle panel shows sensitivity. The models not containing APOEε4 all have lower sensitivity. The bottom
panel shows the size of the screening pool (e.g. web-based registry) that would be
required to recruit 1,000 Aβ+ individuals by applying the given SUVR threshold to
values predicted from each model.
Abbreviations: PPV, Positive Predictive Value; SUVR, Standardized Uptake Value
Ratio; PACC, Preclinical Alzheimer Cognitive Composite; PET, positron emission
tomography

Discussion
This work, in the context of the TRC-PAD platform,
can facilitate the development of participant selection
algorithms. TRC-PAD has two main selection points; the
first is from the APT webstudy to in-clinic assessment
(stage 1) and the second is from in-clinic to amyloid
testing (stage 2). In stage 1, consented webstudy
participants are referred to their nearest TRC-PAD site,
identified via the use of self-reported zip codes. They are
then ranked based on their SUVR prediction. In addition
to this predicted SUVR, the selection process considers
demographics to achieve diversity and if the participant
has known prior amyloid testing and results. During
the first in-clinic visit of the referred participants in stage
1, additional cognitive testing, in the form of the PACC,
and APOE genotyping is performed. With this additional
information, the SUVR predictions are updated and
presented for central authorization of amyloid testing.
This work has shown that by collecting relatively
simple demographics, cognitive and functional
assessments remotely, via the webstudy, we will be able
to reduce screen fail rates and improve enrollment. Even
small improvements in NNS can have a large impact
on the expense of screening for Preclinical AD clinical
trials. For example, assuming a conservative estimate
of 3,500 US Dollars (USD) per scan, the A4 study spent
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a total of about 4,486x3,500(USD) = 15,701,000(USD) for
screening amyloid PET scans alone to identify 1,323 Aβ+
individuals (NNS=3.39). Reducing the NNS from 3.39
to 2.62, which seems plausible with the simplest remote
battery, would have reduced this cost by 3,569,090(USD)
to 1,323x2.62x3,500(USD) = 12,131,910 (USD). In addition
to the remote data setting, this work included the value
of APOE genotyping and collection of PACC during
an in-clinic screening. Adding APOE genotype might
reduce NNS to below 2.00, for a total PET screening cost
of 1,323x2.00x3,500(USD) = 9,261,000(USD). The financial
impact would be less with a cerebrospinal fluid (CSF)based, or blood-based, amyloid screen, but the impact
on subject and site burden would remain significant.
From a statistical aspect, we have demonstrated the use
of Machine Learning Techniques to both optimize, via
Bayesian Optimization, and produce predictive models
using XGBoost. We have illustrated how to make
inferences from a modelling approach that is primarily
used for prediction via the SHAP metric.
One limitation of these pre-screening algorithms is
that the cohort characteristics will be impacted. For
example, we would expect the algorithms to produce an
older cohort with an even greater proportion of APOEε4
carriers than a cohort selected without a pre-screen. This
could be mitigated by stratifying the screening process
to ensure an adequate sample of younger, APOEε4 noncarriers; but with adverse effects on the NNS. Another
consideration is the inability for these models to
extrapolate beyond the data in the continuous variables
such as age. A second potential limitation is in the bias of
the training data. As we start using these models in TRCPAD and collect additional data, we will assess whether
the models are biased against any additional covariates
collected.
Future work will focus on utilizing longitudinal
cognitive and functional change and/or the use of bloodbased biomarkers to improve the performance of these
predictive models and algorithms. We anticipate, based
on analyses of the Alzheimer Disease Neuroimaging
Initiative (ADNI) (5), that longitudinal change may be a
valuable predictor of amyloid status. In addition, we will
incorporate plasma amyloid peptide ratios (currently in
validation testing) into the final stage of prediction and
expect a large improvement in prediction.
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